Search Results - natural+compounds

14 Results

Sort By:

Pharmacological Intervention of the Arachidonic Acid Pathway to Cure Amyotrophic Lateral Sclerosis

Unmet NeedAmyotrophic Lateral Sclerosis (ALS) affects as many as 30,000 people in the United States alone, with 5,000 new cases diagnosed every year. ALS is a fatal neuromuscular disease that is characterized by a progressive degeneration of the motor nerve cells and spinal cord. There are only two drugs approved by FDA for the treatment of ALS, and...

Published: 5/9/2024 | Inventor(s): Gabsang Lee, Hyungjin Eoh, Hojae Lee, Thomas Lloyd, Nicholas Maragakis

Keywords(s): Amyotrophic Lateral Sclerosis, CNS and Neurological Disorders, Disease Indication, Natural compounds, Non-novel, Predicted Novelty, Target, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations > Neurology > Amyotrophic Lateral Sclerosis, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Repurposed Drugs

Identification of Novel Coumestan Derivatives as Pks13 Inhibitors against Mycobacterium Tuberculosis

Unmet NeedTuberculosis (TB) is an infectious disease caused by the bacteria Mycobacterium tuberculosis (Mtb), which typically impacts the lungs. In 2016, there were 10.4 million new cases of TB and 1.7 million deaths worldwide, with approximately one-fourth of the world’s population infected. As a result, TB is one of the leading infectious disease...

Published: 5/9/2024 | Inventor(s): William Bishai, Shichun Lun, Li-Fang Yu, Shu-Huan Wang, Fan Yang, Jie Tang, Hendra Gunosewoyo, Ashlee Earl, Abigail Manson, Wei Zhang

Keywords(s): Antagonists/Inhibitors, Disease Indication, Infectious Diseases, Myobacterium Tuberculosis, Natural compounds, Non-novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Tuberculosis (TB)

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases > Tuberculosis (TB)

Use of C1q/TNF-related Protein-1 (CTRP1) to Treat Fatty Liver Disease (steatosis)

Unmet NeedObesity is a leading preventable cause of death worldwide, and it is associated with a number of comorbidities, including Non-alcoholic Fatty Liver Disease (NAFLD). Fatty liver is the accumulation of triglycerides and other fats in the liver cells. The amount of fatty acid in the liver depends on the balance between the processes of delivery...

Published: 5/9/2024 | Inventor(s): Guang Wong, Susana Rodriguez

Keywords(s): Biologics, Disease Indication, Metabolic Disorders, Natural compounds, Non-novel, Predicted Novelty, Protein, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Metabolic Diseases, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities

Broad Spectrum Chemoprotective Activities of Exemstane Against Cancer and Other Chronic Diseases: Synergism with Sulforaphane

Estrogens control the growth and development of the majority of breast cancers, the most prevalent malignancies of women in the developed world. Exemestane, a synthetic steroid commonly used clinically to prevent, delay progression of, and treat breast cancer, was designed to inhibit estrogen biosynthesis by aromatase. We have made the unexpected observation...

Published: 5/9/2024 | Inventor(s): Hua Liu, Paul Talalay

Keywords(s): Antagonists/Inhibitors, Cancers, Chemotherapy/Chemotherapy, Combination, Disease Indication, Natural compounds, Non-novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

C03416: HIF-1aDP, A Constitutively-Expressed form of Hypoxia-Inducible Factor 1a

C03416: HIF-1aDP, A Constitutively-Expressed form of Hypoxia-Inducible Factor 1a Technical Details: It has previously been demonstrated that a truncation of HIF-1alpha after amino acid residue 390 results in a constitutively expressed form of the protein. The purpose of this work was to identify mechanisms by which the half-life of the HIF1alpha...

Published: 5/9/2024 | Inventor(s): Gregg Semenza

Keywords(s): Biologics, Cardiovascular Diseases, Disease Indication, Gene Therapy, Natural compounds, Non-novel, Predicted Novelty, Protein, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities

Cholesterol Treatment of Autism Spectrum Disorder

C10705: Autism Spectrum Disorder: A Treatment ApproachValue Proposition: While there is no known single cause for autism, Inventors have determined that a population of patients with ASD that is not associated with Smith-Lemli-Opitz Syndrome has plasma sterol levels that are outside the typical range. Preliminary studies by the Inventors suggest that...

Published: 5/9/2024 | Inventor(s): Forbes Porter, Elaine Tierney

Keywords(s): Autism, Biomarker, CNS and Neurological Disorders, Disease Indication, Natural compounds, Non-novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Psychiatry > Autism, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Psychiatry, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Targets

PNU-120596 and 3-(2,4-dimethoxybenzylidene) Anabaseine (GTS-21) (both nAchRa7 agonists) and Methyllycaconitine (anAchRa7 antagonist), are Highly Effective Drugs in Therapy of Ulcerative Colitis (UC) and Crohn's Disease (CD)

C10382: Breakthrough Therapeutic for Inflammatory Bowel Diseases (IBD)Novelty: This technology identifies a nicotinic acetylcholine receptor isoform (nAChR7) that has a prevalent role in affecting Inflammatory Bowel Disease (IBD), as well as several agonist/antagonists to nAChR7, that are highly effective in both the prevention and therapy of ulcerative...

Published: 5/9/2024 | Inventor(s): Philip Alex, Michael Centola, Xuhang Li

Keywords(s): Chronic Inflammatory Diseases, Combination, Crohn's disease, Crohn's Disease, Disease Indication, Gastrointestinal Disorders, Inflammatory Bowel Disease, Inflammatory Bowel Disease (IBD), Natural compounds, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Targeted Therapy/Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Ulcerative Colitis, Ulcerative Colitis (UC)

Rapid Induction of Cancer Cell Death by Synergistic Treatment of Tetra-O-methyl Nordihydroguaiaretic Acid (M4N) with either Rottlerin or Ly294002

Technical Details: M4N is an anti-cancer drug candidate, which is currently under the first phase of clinical trials. Although M4N can reduce tumor cell growth; it fails to induce quick tumor cell death. JHU scientists showed that the combination treatment of M4N with either two specific kinase inhibitors overcomes this problem. In vivo study demonstrated...

Published: 5/9/2024 | Inventor(s): Kotohiko Kimura, Ru Chih Huang

Keywords(s): Antagonists/Inhibitors, Cancers, Chemotherapy/Targeted Therapy, Combination, Disease Indication, Natural compounds, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Development of a Combinational Paradigm Combating HIV, HIV/HSV or HIV/HPV Infections in Humans

Technical Details: WHO report has stated that there are 39.5 million people currently HIV positive worldwide. Of these, 4.3 million have been infected in the year 2006 alone. AIDS death reached 2.9 million this year which is the highest ever reported in any year. There are 40,000 new AIDS cases a year in U.S. along. The anti-HIV compounds that are currently...

Published: 5/9/2024 | Inventor(s): Ru Chih Huang, Ibrahim Abd-Elazem

Keywords(s): Antagonists/Inhibitors, Cancers, Disease Indication, Herpes Simplex Virus, Herpes Simplex Virus (HSV), HIV, HIV/AIDS, Infectious Diseases, Natural compounds, Non-novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Viral Infections

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases > Herpes Simplex Virus, Clinical and Disease Specializations > Infectious Diseases > HIV/AIDS, Clinical and Disease Specializations > Infectious Diseases > Viral Infections, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities

Role of Limonoid Compounds As Neuroprotective Agents

Invention novelty: A series of compounds from the limonoid family that can be used in protecting neurons from different types of toxicity. Unmet Need: Neurodegenerative diseases are characterized by extensive deterioration of neurons or glia. Because these cells are not easily regenerated, there is an emerging unmet medical need for a therapeutic...

Published: 5/9/2024 | Inventor(s): Norman Haughey, Avindra Nath, Joseph Steiner

Keywords(s): CNS and Neurological Disorders, Disease Indication, Multiple CNS Indications, Natural compounds, Neurodegeneration, Neurodegenerative Diseases, Non-novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Neurology > Neurodegeneration, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

1 2